Chagas’ disease: achievements and perspectives in Colombia
Keywords:
Chagas disease
Downloads
Download data is not yet available.
References
1. Guhl F, Lazdings-Helds J, editores. Grupo de trabajo científico: reporte sobre la enfermedad de Chagas. Buenos Aires, Argentina: TDR-WHO y Ginebra, Suiza: PAHO; 2007,
2. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:388-402. 3. World Health Organization. Chagas disease. 2016. Fecha de consulta: 12 de marzo de 2022. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
4. PAHO; WHO. EMTCT - Plus: Framework for elimination of mother-to-child transmission of HIV, syphilis, hepatitis B, and Chagas. 2017. Fecha de consulta: 17 de marzo de 2022. Disponible en: https://iris.paho.org/handle/10665.2/34306
5. Olivera MJ, Buitrago G. Economic costs of Chagas disease in Colombia in 2017: A social perspective. Int J Infect Dis. 2017;91:196-201.
6. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: A computational simulation model. Lancet Infect Dis. 2013;13:342-8.
7. World Bank. The short-term economic costs of Zika in Latin America and the Caribbean. Fecha de consulta: 20 de marzo de 2022. Disponible en: http://pubdocs.worldbank.org/pubdocs/publicdoc/2016/2/410321455758564708/The-short-term-economic-costs-of-Zika-in-LCR-final-doc-autores-feb-18.pdf
8. Chaves GC, Arrieche MAS, Rode J, Mechali D, Reis PO, Alves RV, et al. Estimación de la demanda de medicamentos antichagásicos: una contribución para el acceso en América Latina. Rev Panam Salud Pública. 2017;8;41:e45-e45.
9. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Álvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med. 2006;144:724-34.
10. Fabbro DL, Streiger ML, Arias ED, Bizai ML, Del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: Parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40:1-10.
11. Sosa-Estani S, Cura E, Velázquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop. 2009;42:484-7. Fecha de acceso: 16 de febrero de 2020. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19967227
12. Moscatelli G, Moroni S, García-Bournissen F, Ballering G, Bisio M, Freilij H, et al. Prevention of congenital chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110:507-9.
13. Murcia L, Simón M, Carrilero B, Roig M, Segovia M. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215:1452-8. Fecha de acceso: 16 de febrero de 2020. Disponible en: https://academic.oup.com/jid/article-abstract/215/9/1452/2993887
14. Uribe C. Infeccion de Rhodnius prolixus (Stahl) por Trypanosoma cruzi y Tripanosoma rangeli. Bogotá, Editorial Minerva: 1929.
15. Corredor A, Santacruz MM, Páez-Gómez S, Guatame LA. Distribucion de los triatominos domiciliarios en Colombia. Bogotá: Instituto Nacional de Salud; 1990.
16. Silvestre de Sousa A, Vermeij D, Parra-Henao G, Lesmo V, Fortún Fernández E, Chura Aruni JJ, et al. The CUIDA Chagas Project: Towards the elimination of congenital
transmission of Chagas disease in Bolivia, Brazil, Colombia, and Paraguay. Rev Soc Bras Med Trop. 2022;29;55:e01712022.
https://doi.org/10.1590/0037-8682-0171-2021. eCollection 2022
2. Rassi A, Rassi A, Marin-Neto JA. Chagas disease. Lancet. 2010;375:388-402. 3. World Health Organization. Chagas disease. 2016. Fecha de consulta: 12 de marzo de 2022. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/chagas-disease-(american-trypanosomiasis)
4. PAHO; WHO. EMTCT - Plus: Framework for elimination of mother-to-child transmission of HIV, syphilis, hepatitis B, and Chagas. 2017. Fecha de consulta: 17 de marzo de 2022. Disponible en: https://iris.paho.org/handle/10665.2/34306
5. Olivera MJ, Buitrago G. Economic costs of Chagas disease in Colombia in 2017: A social perspective. Int J Infect Dis. 2017;91:196-201.
6. Lee BY, Bacon KM, Bottazzi ME, Hotez PJ. Global economic burden of Chagas disease: A computational simulation model. Lancet Infect Dis. 2013;13:342-8.
7. World Bank. The short-term economic costs of Zika in Latin America and the Caribbean. Fecha de consulta: 20 de marzo de 2022. Disponible en: http://pubdocs.worldbank.org/pubdocs/publicdoc/2016/2/410321455758564708/The-short-term-economic-costs-of-Zika-in-LCR-final-doc-autores-feb-18.pdf
8. Chaves GC, Arrieche MAS, Rode J, Mechali D, Reis PO, Alves RV, et al. Estimación de la demanda de medicamentos antichagásicos: una contribución para el acceso en América Latina. Rev Panam Salud Pública. 2017;8;41:e45-e45.
9. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, Álvarez MG, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: A nonrandomized trial. Ann Intern Med. 2006;144:724-34.
10. Fabbro DL, Streiger ML, Arias ED, Bizai ML, Del Barco M, Amicone NA. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: Parasitological, serological and clinical evolution. Rev Soc Bras Med Trop. 2007;40:1-10.
11. Sosa-Estani S, Cura E, Velázquez E, Yampotis C, Segura EL. Etiological treatment of young women infected with Trypanosoma cruzi, and prevention of congenital transmission. Rev Soc Bras Med Trop. 2009;42:484-7. Fecha de acceso: 16 de febrero de 2020. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/19967227
12. Moscatelli G, Moroni S, García-Bournissen F, Ballering G, Bisio M, Freilij H, et al. Prevention of congenital chagas through treatment of girls and women of childbearing age. Mem Inst Oswaldo Cruz. 2015;110:507-9.
13. Murcia L, Simón M, Carrilero B, Roig M, Segovia M. Treatment of infected women of childbearing age prevents congenital Trypanosoma cruzi infection by eliminating the parasitemia detected by PCR. J Infect Dis. 2017;215:1452-8. Fecha de acceso: 16 de febrero de 2020. Disponible en: https://academic.oup.com/jid/article-abstract/215/9/1452/2993887
14. Uribe C. Infeccion de Rhodnius prolixus (Stahl) por Trypanosoma cruzi y Tripanosoma rangeli. Bogotá, Editorial Minerva: 1929.
15. Corredor A, Santacruz MM, Páez-Gómez S, Guatame LA. Distribucion de los triatominos domiciliarios en Colombia. Bogotá: Instituto Nacional de Salud; 1990.
16. Silvestre de Sousa A, Vermeij D, Parra-Henao G, Lesmo V, Fortún Fernández E, Chura Aruni JJ, et al. The CUIDA Chagas Project: Towards the elimination of congenital
transmission of Chagas disease in Bolivia, Brazil, Colombia, and Paraguay. Rev Soc Bras Med Trop. 2022;29;55:e01712022.
https://doi.org/10.1590/0037-8682-0171-2021. eCollection 2022
How to Cite
1.
Parra-Henao G, Vera MJ. Chagas’ disease: achievements and perspectives in Colombia. Biomed. [Internet]. 2022 Jun. 1 [cited 2025 Apr. 12];42(2):213-7. Available from: https://revistabiomedicaorg.biteca.online/index.php/biomedica/article/view/6618
Some similar items:
- Myriam C. López, Sofía Duque, Luis C. Orozco, Diana Camargo, Luis E. Gualdrón, Elvia Cáceres, Margarita Ronderos, Maritza Rey, Augusto Corredor, lmmunodiagnosis of Chagas' disease by ELlSA , Biomedica: Vol. 19 No. 2 (1999)
- Luis C. Orozco, Diana Camargo, Myriam C. López, Sofía Duque, Luis E. Gualdrón, Elvia Cáceres, Margarita Ronderos, Maritza Rey, Augusto Corredor, Immunodiagnosis of Trypanosoma cruzi infection in humans using ELISA on blood collected on filter paper , Biomedica: Vol. 19 No. 2 (1999)
Published
2022-06-01
Issue
Section
Editorial
Altmetric
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
